^
    1m
    A Real World Study of Elranatamab in Patients With RR Multiple Myeloma in Taiwan (clinicaltrials.gov)
    P=N/A, N=1, Active, not recruiting, Pfizer | Not yet recruiting --> Active, not recruiting | N=30 --> 1
    Enrollment closed • Enrollment change • Real-world evidence
    |
    Elrexfio (elranatamab-bcmm)
    1m
    Influence of PPM1D Mutations on Response and Survival Outcomes Following Bispecific Antibody Therapy in Relapsed and Refractory Multiple Myeloma Patients. (PubMed, Biomedicines)
    We conducted a retrospective, single-center study including 27 patients with RRMM who were treated with bsAbs (teclistamab, elranatamab, or talquetamab) between June 2022 and September 2025 and for whom genetic material was available before bsAB treatment. These findings suggest that PPM1D mutations may represent a promising biomarker in patients with RRMM treated with bsAbs. Larger, prospective studies are warranted to validate and further elucidate these observations.
    Journal
    |
    PPM1D (Protein Phosphatase Mg2+/Mn2+ Dependent 1D)
    |
    Elrexfio (elranatamab-bcmm) • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    AugMMent: GMMG-HD11/DSMM XXI/64007957MMY3010 (clinicaltrials.gov)
    P3, N=399, Not yet recruiting, University of Heidelberg Medical Center
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • melphalan • Tecvayli (teclistamab-cqyv)
    2ms
    TRIlogy-7: A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned (clinicaltrials.gov)
    P3, N=1000, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • ramantamig (JNJ-5322) • dexamethasone injection
    2ms
    Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy (clinicaltrials.gov)
    P1, N=6, Active, not recruiting, Regeneron Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Mar 2028 --> Aug 2027 | Trial primary completion date: Mar 2028 --> Aug 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Dupixent (dupilumab) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital | Initiation date: Apr 2026 --> Aug 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    2ms
    LINKER-MM8: A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) (clinicaltrials.gov)
    P2/3, N=0, Withdrawn, Regeneron Pharmaceuticals | N=1570 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)
    2ms
    Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. (PubMed, Hemasphere)
    Patients receiving immunoglobulin replacement therapy had a 2.01 lower risk of infections Grade 3 or 4 and a 6.14 lower risk of death. Our findings demonstrate the efficacy of teclistamab in a heavily diseased and pretreated cohort with AL amyloidosis and highlight the necessity of a concomitant immunoglobulin replacement therapy.
    Clinical • Retrospective data • Journal
    |
    NPPB (Natriuretic Peptide B)
    |
    Tecvayli (teclistamab-cqyv)
    2ms
    CAREMM-011: CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    lenalidomide • bortezomib • Sarclisa (isatuximab-irfc)
    2ms
    64007957MMY2022: A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination withnPomalidomide Administered in Alternative Fashion in Participants with RRMM, whonReceived 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy (2025-522114-23-00)
    P1/2, N=35, Not yet recruiting, Odense University Hospital
    New P1/2 trial
    |
    lenalidomide • pomalidomide • Tecvayli (teclistamab-cqyv)
    2ms
    Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=8, Terminated, Second Affiliated Hospital of Xi'an Jiaotong University | N=34 --> 8 | Not yet recruiting --> Terminated; Achieved the proof of concept
    Enrollment change • Trial termination
    2ms
    A Trial in Healthy Adult Participants and Adults With Autoimmune Disease to Test How HBM7020 is Tolerated and Absorbed in the Body (clinicaltrials.gov)
    P1, N=63, Not yet recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc.
    New P1 trial • First-in-human